INS and Hyperglycemia: Remarkably, it not only demonstrated the ability to overcome resistance mediated by secondary PI3Kα mutations but also minimized the impact on insulin signaling, reducing hyperglycemia and allowing for higher target engagement and a wider therapeutic index [145].